IMV Inc IMVIF

Thoughts on the updates today?

[alphaseeking001]

Thoughts ladies and gents?  Seems positive to me but would appreciate all thoughts.  Cheers

[Jthom376]

Another quarter of waiting is my take... which translates to all of 2021. Didn't really have a lot... gave a drug a name no one will be able to say. Not bad... just similar to every other conference. Was hoping for something extremely strong. Didn't repeat the Q1 potential COVID launch Ors stated on the HCW conference a week ago... 

[Biotech010]

It was a smart move to have Andrew on the call, the director of business development.The last question on the Q&A was good, DPX goes beyond Ovarian DLBCL etc so there is room for lots of partners. They hope to realize a partnership in 2021. Obviously, there will be collab agreemnet with Merck on the phase 2b in DLBCL. We're going to hear on that trial in Q1.

[Hideaway]

Market reaction to update not encouraging.We are moving to slow to hold investor interest.The basket trial update does not help our cause. However,there was nothing disastrous announced and hope that the update before end of quarter will be a bit more positive.Based on past history,not too hopeful but will continue holding for next update.

[alphaseeking001]

Thanks Hideaway.  Yes, frustrating as usual.  I will be holding as well.  Would be interested to here others thoughts as well.  QM45 any thoughts?

[qwerty22]

Basket - frustrating, lack of detail is painful. From the Q&A section sounds like we aren't going to get that detail any time soon, they want to wait for duration, dive into the supporting data and publish (sounds looooong). While moving forward with 2 out of 5 is a reasonable outcome the lack of detail really doesn't help in supporting/validating the dlbcl position (well it doesn'

[qwerty22]

Here is the pembro MSI-H data, it already has approval. https://clincancerres.aacrjournals.org/content/clincanres/early/2019/06/04/1078-0432.CCR-18-4070.full.pdf So based on what was said in the call about bladder and this in MSI-H then we really are looking at continuation in indications where pembro is already active. What does this say? My first thought is it would be better to move the